Created at	Source	Raw Value	Validated value
July 21, 2021, 4 p.m.	usa	Geometric mean fold increase of neutralizing antibody against SARS-CoV-2;Geometric mean fold increase of neutralizing antibody against SARS-CoV-2;GMT of neutralizing antibody against SARS-CoV-2;GMT of neutralizing antibody against SARS-CoV-2;GMT of neutralizing antibody against SARS-CoV-2;Occurrence of adverse reactions and the percentage of subjects with ≥ Grade 3 adverse events	Geometric mean fold increase of neutralizing antibody against SARS-CoV-2;Geometric mean fold increase of neutralizing antibody against SARS-CoV-2;GMT of neutralizing antibody against SARS-CoV-2;GMT of neutralizing antibody against SARS-CoV-2;GMT of neutralizing antibody against SARS-CoV-2;Occurrence of adverse reactions and the percentage of subjects with ≥ Grade 3 adverse events